Eli Lilly downgrades after underwhelming report, though diabetes business advances
The US-based pharmaceutical firm has adjusted its earnings per share forecast following a quarter with fewer sales than analysts had expected.
by marketwire, translated by daniel pedersen
On Thursday, Eli Lilly publicized its second quarter figures for 2022 alongside a guidance downgrade containing a revised expectation for its earnings per share to USD 7.9–8.05 from a previous USD 8.15–8.3.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly squares up to Novo Nordisk on obesity market
For subscribers
